文献速递精神分裂症与精神病性障碍

抗精神病药治疗精神分裂症的疗效与效果:整合随机对照试验与真实世界数据的网络荟萃分析

Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data.
PubMed 文献 · Lancet Psychiatry · 2024-01-09

该研究整合瑞典和芬兰国家登记库的个体数据与随机对照试验聚合数据,采用网络荟萃分析比较抗精神病药预防精神分裂症复发的疗效与效果。结果显示,真实世界中长效注射剂效果略优于随机对照试验结果,药物间比较总体一致,但随机对照试验可能高估常规诊疗中的药物效果。

要点

  • 真实世界中长效注射剂效果略优于随机对照试验所见。
  • 随机对照试验可能高估常规诊疗中抗精神病药的效果。
  • 氯氮平在真实世界网络荟萃分析中效果最优。

核心结论

  • 长效注射抗精神病药在真实世界中的效果略优于随机对照试验结果,其他药物间比较随机对照试验证据与真实世界证据总体一致,但随机对照试验可能高估常规诊疗中观察到的抗精神病药效果。

研究设计与样本

  • 研究使用瑞典和芬兰国家登记库的个体参与者数据以及随机对照试验的聚合数据,开展网络荟萃分析。
  • 目标人群为年龄大于18岁且小于65岁、症状稳定的精神分裂症或分裂情感性障碍成人。
  • 主要结局为抗精神病药起始后6个月内复发的风险比(HR)及95%CI。

主要发现

  • 瑞典与芬兰登记库中抗精神病药的效果一致性良好,HR比值为0·97(95%CI 0·88-1·08)。
  • 随机对照试验合格者中药物效果相对于无抗精神病药使用大于不合格者,HR比值为1·40(95%CI 1·24-1·59)。
  • 随机对照试验中药物相对于安慰剂的疗效大于真实世界中相对于无抗精神病药使用的效果,HR比值为2·58(95%CI 2·02-3·30)。
  • 药物间比较的效果与疗效无差异证据(相对于口服氟哌啶醇的HR比值为1·17,95%CI 0·83-1·65),但长效注射剂与口服剂比较例外(HR比值为0·73,95%CI 0·53-0·99)。
  • 真实世界网络荟萃分析显示氯氮平最有效,其次为奥氮平长效注射剂;联合网络荟萃分析中奥氮平为最有效抗精神病药之一。

关键数值与推荐

  • 共纳入瑞典和芬兰登记库的90 469名个体(平均年龄45·9岁,SD 14·6;女性43 025人[47·5%],男性47 467人[52·5%])和来自30项随机对照试验的10 091名个体(平均年龄39·6岁,SD 11·7;女性3724人[36·9%],男性6367人[63·1%],白人6022人[59·7%])。
  • 真实世界网络荟萃分析中氯氮平最有效,其次为奥氮平长效注射剂。
  • 联合真实世界与随机对照试验的网络荟萃分析确定奥氮平为同时存在于随机对照试验和真实世界登记库中的最有效抗精神病药之一。

临床怎么用

  • 长效注射抗精神病药在真实世界中的效果略优于随机对照试验结果,支持在常规诊疗中考虑使用。
  • 随机对照试验可能高估抗精神病药在常规诊疗中的效果,临床决策需结合真实世界证据。
  • 结果有助于理解随机对照试验发现向临床实践的外推性,并可为优先处方指南提供参考。

局限性

  • 随机对照试验网络荟萃分析存在异质性和不一致性。
  • 登记库数据缺乏 ethnicity 信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is debate about the generalisability of results from randomised clinical trials (RCTs) to real-world settings. Studying outcomes of treatments for schizophrenia can shed light on this issue and inform treatment guidelines. We therefore compared the efficacy and effectiveness of antipsychotics for relapse prevention in schizophrenia and estimated overall treatment effects using all available RCT and real-world evidence. METHODS: We conducted network meta-analyses using individual participant data from Swedish and Finnish national registries and aggregate data from RCTs. The target population was adults (age >18 and <65 years) with schizophrenia and schizoaffective disorder with stabilised symptoms. We analysed each registry separately to obtain hazard ratios (HRs) and 95% CIs for relapse within 6 months post-antipsychotic initiation as our main outcome. Interventions studied were antipsychotics, no antipsychotic use, and placebo. We compared HRs versus a reference drug (oral haloperidol) between registries, and between registry individuals who would be eligible and ineligible for RCTs, using the ratio of HRs. We synthesised evidence using network meta-analysis and compared results from our network meta-analysis of real-world data with our network meta-analysis of RCT data, including oral versus long-acting injectable (LAI) formulations. Finally, we conducted a joint real-world and RCT network meta-analysis. FINDINGS: We included 90 469 individuals from the Swedish and Finnish registries (mean age 45·9 [SD 14·6] years; 43 025 [47·5%] women and 47 467 [52·5%] men, ethnicity data unavailable) and 10 091 individuals from 30 RCTs (mean age 39·6 years [SD 11·7]; 3724 [36·9%] women and 6367 [63·1%] men, 6022 White [59·7%]). We found good agreement in effectiveness of antipsychotics between Swedish and Finnish registries (HR ratio 0·97, 95% CI 0·88-1·08). Drug effectiveness versus no antipsychotic was larger in RCT-eligible than RCT-ineligible individuals (HR ratio 1·40 [1·24-1·59]). Efficacy versus placebo in RCTs was larger than effectiveness versus no antipsychotic in real-world (HR ratio 2·58 [2·02-3·30]). We found no evidence of differences between effectiveness and efficacy for between-drug comparisons (HR ratio vs oral haloperidol 1·17 [0·83-1·65], where HR ratio >1 means superior effectiveness in real-world to RCTs), except for LAI versus oral comparisons (HR ratio 0·73 [0·53-0·99], indicating superior effectiveness in real-world data relative to RCTs). The real-world network meta-analysis showed clozapine was most effective, followed by olanzapine LAI. The RCT network meta-analysis exhibited heterogeneity and inconsistency. The joint real-world and RCT network meta-analysis identified olanzapine as the most efficacious antipsychotic amongst those present in both RCTs and the real world registries. INTERPRETATION: LAI antipsychotics perform slightly better in the real world than according to RCTs. Otherwise, RCT evidence was in line with real-world evidence for most between-drug comparisons, but RCTs might overestimate effectiveness of antipsychotics observed in routine care settings. Our results further the understanding of the generalisability of RCT findings to clinical practice and can inform preferential prescribing guidelines. FUNDING: None.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Efthimiou O, Taipale H, Radua J, et al. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data. Lancet Psychiatry. 2024. PMID: 38215784. doi:10.1016/S2215-0366(23)00366-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。